Full Press Release Details
| NEWS RELEASE | FOR IMMEDIATE RELEASE | |
| For Further Information Contact: | ||
| Patrick J. McEnany | Melody Carey | |
| Catalyst Pharmaceutical Partners | Rx Communications Group | |
| Chief Executive Officer | Co-President | |
| (305) 529-2522 | (917) 322-2571 | |
| pmcenany@catalystpharma.com | mcarey@rxir.com |
Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results
CORAL GABLES, FL, May 16, 2013 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced financial results for the three month period ended March 31, 2013.
Patrick J. McEnany, Catalyst s Chief Executive Officer, Since the beginning of 2013, we have made solid progress towards completion of our
2013 corporate goals. We have completed the transfer of the Firdapse program from BioMarin and have started to add additional patients into the LMS-002 clinical trial for Firdapse to treat Lambert-Eaton Myasthenic Syndrome (LEMS). We
have also made progress towards the opening of additional clinical trial sites in the U.S. and Europe. In that regard, we intend to regularly update the market regarding the status of our development efforts for Firdapse as these matters
Catalyst reported a GAAP net loss of $1,744,289, or $0.04 per basic and diluted share, compared to a GAAP net loss of $1,089,186, or $0.04 per basic and diluted share, for the same period in 2012.
Excluding non-cash expense of $45,326 attributable to the change in fair value of liability-classified warrants,
Non-GAAP1 net loss was $1,698,963, or $0.04 per share for
the first quarter of 2013. In
comparison, Non-GAAP1 net loss for the first quarter of 2012 was $1,363,393, or $0.06 per share, which excludes non-cash income of $274,207 attributable to the change in fair value of liability-classified warrants.
Research and development expenses for the first quarter of 2013 were $1,092,301, compared to $727,327 in the first quarter of 2012. Research
and development expenses increased when compared to the same period in 2012 as Catalyst expanded its activities associated with the currently ongoing phase III trial evaluating Firdapse for the treatment of LEMS. Catalyst expects that research
and development expenses will increase during 2013 as a result of the ongoing development projects for Firdapse .
administrative expenses for the first quarter of 2013 totaled $613,129, compared to $637,383 in the first quarter of 2012.
development-stage specialty pharmaceutical company, Catalyst had no revenues in either the first quarter of 2013 or the first quarter of 2012.
At March 31, 2013, Catalyst had cash and cash equivalents, certificates of deposit and short-term investments of $13.2 million and no debt. Catalyst
believes that its existing cash and investments will be sufficient to meet its projected operating requirements through the first quarter of 2014.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is
a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms,
and Tourette Syndrome. Catalyst s lead candidate, Firdapse for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome, and movement disorders
associated with the treatment of Parkinson s Disease.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause
Catalyst s actual results in future periods to differ materially from forecasted results. A number of factors, including whether the Phase III trial evaluating Firdapse for the treatment of LEMS will be successful, whether the Phase III
trial will be completed on the expected timeline, whether Catalyst has sufficient resources to meet its projected operating requirements through the first quarter of 2014, as well as those factors described in Catalyst s Annual Report on Form
10-K for the fiscal year 2012 and other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst s filings with the SEC are available from the SEC, may be found on Catalyst s
website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
CONDENSED STATEMENTS OF OPERATIONS (unaudited)
| For the Three Months Ended March 31, | ||||||||
| 2013 | 2012 | |||||||
| Revenues government grant | $ | $ | ||||||
| Operating costs and expenses: | ||||||||
| Research and development | 1,092,301 | 727,327 | ||||||
| General and administrative | 613,129 | 637,383 | ||||||
| Total operating costs and expenses | 1,705,430 | 1,364,710 | ||||||
| Loss from operations | (1,705,430 | ) | (1,364,710 | ) | ||||
| Interest income | 6,467 | 1,317 | ||||||
| Change in fair value of warrants liability | (45,326 | ) | 274,207 | |||||
| Loss before income taxes | (1,744,289 | ) | (1,089,186 | ) | ||||
| Provision for income taxes | ||||||||
| Net loss | $ | (1,744,289 | ) | $ | (1,089,186 | ) | ||
| Net loss per share basic and diluted | $ | (0.04 | ) | $ | (0.04 | ) | ||
| Weighted average shares outstanding basic and diluted | 41,420,687 | 24,710,362 |
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
| March 31, 2013 | December 31, 2012 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 646,045 | $ | 1,409,939 | ||||
| Certificates of deposit | 5,005,380 | 6,502,825 | ||||||
| Short-term investments | 7,507,146 | 7,504,444 | ||||||
| Prepaid expenses | 1,242,785 | 1,309,470 | ||||||
| Total current assets | 14,401,356 | 16,726,678 | ||||||
| Property and equipment, net | 57,747 | 53,679 | ||||||
| Deposits | 8,888 | 8,888 | ||||||
| Total assets | $ | 14,467,991 | $ | 16,789,245 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 567,185 | $ | 1,365,663 | ||||
| Accrued expenses and other liabilities | 416,050 | 281,002 | ||||||
| Total current liabilities | 983,235 | 1,646,665 | ||||||
| Accrued expenses and other liabilities, non-current | 21,265 | 21,878 | ||||||
| Warrants liability, at fair value | 543,913 | 498,587 | ||||||
| Total liabilities | 1,548,413 | 2,167,130 | ||||||
| Total stockholders equity | 12,919,578 | 14,622,115 | ||||||
| Total liabilities and stockholders equity | $ | 14,467,991 | $ | 16,789,245 |